Balchem Corporation · NASDAQ:BCPC
Balchem — Investor Presentation (July 2020)
29 slides from Balchem's investor presentation, Jul 31, 2020
Slide 1: Investor Presentation Q2 2020
Investor Presentation Q2 2020 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • We will attempt to identify these statements by use of words such as expect, believe, anticipate, intend, and other words that denote fu
Slide 3: Balchem Corporation
Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that help make the world a healthier place Highlights • NASDAQ: BCPC • Founded in 1967 • Headquarters: New Hampton, NY • Approximately 1,400 Employees • 21 Manufacturing Sites: - 17 in North America - 3 in Europe -
Slide 4: Leadership
Leadership Ted Harris, Chairman and CEO • Joined Balchem in May 2015 • Prior to Balchem was a Senior VP of Ashland Inc. where he held a series of senior leadership roles over 10+ years • Independent director and member of the Board of Directors of Pentair plc. • MBA from Harvard University and bache
Slide 5: Balchem at a Glance
Balchem at a Glance OTHER 4% SPECIALTY PRODUCTS 14% 96% HUMAN NUTRITION & HEALTH Nutrition & Health (% of FY 2019 sales) 54% ANIMAL NUTRITION & HEALTH 28% 96% Of Revenues Focused On Nutrition And Health 5
Slide 6: Segment Overview
Segment Overview Segment Markets Served Solutions 4% 14% Human Nutrition • Nutritional Supplements • Microencapsulation 96% & Health • Food and Beverage • Choline Nutrition & Health (% of sales) • Infant & Toddler Formula • Chelated Minerals 54% 28% • Organic Cereal • Powder, Flavor, & Cereal System
Slide 7: Vision and Mission
Vision and Mission Our vision is clear; to make the world a healthier place Our mission is to build a global nutrition and health company delivering trusted, innovative, and science based solutions to our customers Committed To Building A Global Nutrition And Health Company 7
Slide 8: Strategic Focus
Strategic Focus • Strengthening Positions in Attractive, Growing Markets – Building scale, adding adjacent capabilities, expanding market and geographic reach, broadening our portfolio of solutions, investing in new science, enabling market awareness • Driving Organic Growth – Creating new demand th
Slide 9: Balchem Growth Platforms
Balchem Growth Platforms Human Nutrition & Health Animal Nutrition & Health HUMAN NUTRITION & HEALTH ANIMAL NUTRITION & HEALTH • Leveraging Synergies Across Segment • ReaShure® Penetration • FDA RDI for Choline and Expanded Choline • NRC Recommendation on Choline Awareness / Science • Rumen Protecte
Slide 10: Growth Vectors
Growth Vectors Growth over 5 years Key Platforms Driving Growth Above Market • Choline and Mineral Nutrition for Mother & Child, Adult Cognition, Energy & Fitness, Liver Health, Diabetes Complications • ReaShure® Penetration Strategic Acquisitions • Rumen Protected Delivery Systems • Companion Anima
Slide 11: COVID-19 Pandemic Response Update
COVID-19 Pandemic Response Update • Our focus has been on employee safety first, keeping our manufacturing sites operational, and satisfying customer needs. To date; – all of our manufacturing sites are operating at near normal conditions, – our research and development teams continue to advance our
Slide 12: Q2 2020 Financial Summary
Q2 2020 Financial Summary Sales Adj. EBITDA Adj. Net Earnings Adj. EPS ($M) ($M) ($M) ($/share) 7.3% 9.8% 9.2% 9.6% 27.6 0.85 173.4 43.9 25.2 0.77 161.6 40.0 2Q19 2Q20 2Q19 2Q20 2Q19 2Q20 2Q19 2Q20 • Growth in all Segments • 57bps expansion YoY • Sales growth translating • Growth in earnings
Slide 13: Historical Financials
Historical Financials SALES ($M) ADJ. EBITDA ($M) 644 644 159 160 595 149 148 541 552 553 140 122 348 86 2014 2015 2016 2017 2018 2019 1H 2020 2014 2015 2016 2017 2018 2019 1H 2020 ADJ. NET EARNINGS ($M) ADJ. EPS ($/share) 3.19 104 3.01 98 2.51 2.52 2.53 80 80 82 2.21 69 54 1.66 2014 2015 2016 2017
Slide 14: Segment Financials
Segment Financials SALES ($M) ADJ. EBITDA ($M) 159 160 644 644 149 5 26 148 10 595 51 140 3 7 552 553 541 48 92 7 39 76 32 25 122 32 54 32 73 70 28 Other 105 54 19 176 178 Other SP 54 158 37 29 33 33 86 161 348 25 166 4 SP 35 56 22 ANH 176 95 ANH 30 19 341 347 80 84 83 316 78 278 297 71 HNH 206 193
Slide 15: Capital Allocation Strategy and M&A
Capital Allocation Strategy and M&A Capital Allocation Strategy Annual Cash Flow ($M) and Debt Leverage Ratio • Prioritize organic growth investments • Augment organic growth with targeted M&A 2.3x 124 • Pay down debt 1.5x 1.6x 119 111 108 104 • Continue to pay and grow dividend 1.2x 1.1x 0.9x 85 0.
Slide 16: Recent Acquisitions
Recent Acquisitions Rationale Key Offering Zumbro River Brand Market consolidation and expanded High protein extrusion and December 2019 product offering agglomeration Chemogas Adds leadership position in Europe to Ethylene Oxide re-packaging and May 2019 already existing U.S. leadership distributio
Slide 17: Free Cash Flow Conversion
Free Cash Flow Conversion 130% Free Cash Flow as % of Non-GAAP Net Earnings 120% 110% 105% 105% 102% 102% 101% 100% 93% 90% 79% 80% 70% 60% 50% 2014 2015 2016 2017 2018 2019 1H 2020 Free Cash Flow Conversion Solid Free Cash Flow Conversion, Turning Profits Into Cash 17
Slide 18: Dividends
Dividends • Yearly double-digit dividend growth for the last decade 0.52 • Consistency in execution 0.47 0.42 0.38 0.34 0.30 ($/share) 0.26 0.22 0.18 0.15 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Consistent Dividend Policy 18
Slide 19: Our Sustainability Framework
Our Sustainability Framework Every day, Balchem is delivering trusted solutions that enhance health and well-being through science. The two objectives of our sustainability strategy directly support our mission of making the world a healthier place: • providing innovative solutions for the health an
Slide 20: Our Sustainability Framework
Our Sustainability Framework People Planet Profit 10.7 billion – number of animals reached per year 24.7% – revenue from products developed in the past 1.4 billion – number of people reached per year five years 0.59 GJ – energy intensity (GJ of energy per ton of 1.32 – total recordable injury rate (
Slide 21: What Makes Balchem Unique?
What Makes Balchem Unique? Proven Track Record Of Growth Protected Positions ✓ Proven ability to grow in in all economic ✓ Consolidated position in Choline conditions ✓ EPA Registrations for EO and PO ✓ Steady and thoughtful capital allocation ✓ Patent portfolio and premium branded ✓ Continued innov
Slide 22: Summary / Wrap Up
Summary / Wrap Up • Leading Positions in Attractive Markets • Creating New Demand Through Innovation • Delivering Healthy Margins • Generating Cash Flow from Operations Available for Reinvestment • Proven Track Record Reasons To Invest 22
Slide 23: Confidential
- baichem * Solve Today. Shape Tomorrow. Confidential 23
Slide 24: Appendix
Appendix 24
Slide 25: Non-GAAP Financial Information
Non-GAAP Financial Information Non-GAAP Financial Information In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding a
Slide 26: Non-GAAP Financial Information - Continued
Non-GAAP Financial Information - Continued 26
Slide 27: Non-GAAP Financial Information - Continued
Non-GAAP Financial Information - Continued 27
Slide 28: Non-GAAP Financial Information - Continued
Non-GAAP Financial Information - Continued 28
Slide 29: Non-GAAP Financial Information - Continued
Non-GAAP Financial Information - Continued 29